Karuna Therapeutics Past Earnings Performance
Past criteria checks 0/6
Karuna Therapeutics's earnings have been declining at an average annual rate of -51.9%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 46.1% per year.
Key information
-51.9%
Earnings growth rate
105.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 46.1% |
| Return on equity | -34.6% |
| Net Margin | -66,311.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Karuna Therapeutics: Getting Sold Short
Feb 18We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely
Sep 26
We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate
Jun 05Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation
Feb 20Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Nov 06Best Performing Stocks
Sep 23Karuna Therapeutics: This Ship Has Sailed
Sep 09Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M
Aug 08Karuna Therapeutics: Front-Running KarXT Phase 3
Jun 26Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans
May 10Revenue & Expenses BreakdownBeta
How Karuna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -434 | 131 | 364 |
| 30 Sep 23 | 6 | -396 | 108 | 348 |
| 30 Jun 23 | 6 | -354 | 95 | 306 |
| 31 Mar 23 | 11 | -316 | 85 | 266 |
| 31 Dec 22 | 11 | -276 | 75 | 224 |
| 30 Sep 22 | 42 | -228 | 71 | 203 |
| 30 Jun 22 | 42 | -202 | 65 | 180 |
| 31 Mar 22 | 37 | -172 | 57 | 152 |
| 31 Dec 21 | 37 | -144 | 52 | 128 |
| 30 Sep 21 | 0 | -140 | 41 | 97 |
| 30 Jun 21 | 0 | -108 | 36 | 71 |
| 31 Mar 21 | 0 | -90 | 33 | 57 |
| 31 Dec 20 | 0 | -69 | 28 | 43 |
| 30 Sep 20 | 0 | -52 | 23 | 33 |
| 30 Jun 20 | 0 | -43 | 21 | 26 |
| 31 Mar 20 | 0 | -41 | 22 | 22 |
| 31 Dec 19 | 0 | -44 | 21 | 25 |
| 30 Sep 19 | 0 | -45 | 18 | 26 |
| 30 Jun 19 | 0 | -42 | 15 | 22 |
| 31 Mar 19 | 0 | -27 | 7 | 17 |
| 31 Dec 18 | 0 | -18 | 3 | 12 |
Quality Earnings: KRTX is currently unprofitable.
Growing Profit Margin: KRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRTX is unprofitable, and losses have increased over the past 5 years at a rate of 51.9% per year.
Accelerating Growth: Unable to compare KRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: KRTX has a negative Return on Equity (-34.58%), as it is currently unprofitable.